Biogen's Alzheimer's disease drug Aduhelm will only be covered for Medicare beneficiaries participating in a clinical trial. The final coverage determination will have the effect of limiting use of the drug, but the agency said its decision provides clarity on what drug companies need to show in order to secure Medicare coverage.
TSX Venture Exchange has a strong history of helping early stage health and life sciences companies raise patient capital for research and development purposes.
Patients are comfortable with pharmacists being more involved, and physicians place a high level of trust in them as well. That mirrors pharmacists' own confidence in their abilities to serve as a resource for everything from drug interactions to medication management.
No comments